Researchers at the University of Vienna are hopeful that the new AD5-10 antibody will lead the way in fighting ovarian cancer.
According to AFP, the antibody works by weakening the resistance of the cancer cells to a natural resistance mechanism. By reducing the resistance of tumors on the protein Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL), the protein induces tumor cells to commit suicide.
Although some of the tumor cells fail to respond to the suicide message, the promising findings published on Monday, certainly offer hope for future treatment. Michael Krainer, who led the study for the Austrian research team said: “We were able to show in both cell cultures and animal models that TRAIL resistant ovarian cancer tumor cells become sensitive to TRAIL again if TRAIL and AD5-10 are both present at the same time.”
The antibody has also been proven to boost the effects of several drugs used in chemotherapy. “We were able to show in cell cultures that the combined effect of AD5-10 and carboplatin (a common chemotherapy agent) was greater than the sum of their effects when administered individually,” said Krainer.
According to the American Cancer Society, approximately 21,550 new cases of ovarian cancer were diagnosed in the US last year and it remains the most fatal form of disease affecting the female reproductive organs.
Originally published on TONIC